Abstract
The De Ritis ratio (AST/ALT) is emerging as a potential prognostic marker for various malignancies. This protocol outlines a systematic review and meta-analysis designed to evaluate the predictive value of the De Ritis ratio regarding survival outcomes in patients with bladder cancer. By synthesizing existing retrospective data, this study aims to provide high-level evidence for the clinical utility of this cost-effective biomarker.
Introduction
Bladder cancer remains a significant oncological challenge, characterized by high recurrence rates and a critical need for personalized treatment strategies. Accurate prognostic markers are essential for clinical decision-making; however, many current biomarkers are invasive, expensive, or difficult to implement in routine practice.
The De Ritis ratio—the ratio of aspartate aminotransferase (AST) to alanine aminotransferase (ALT)—is a simple, blood-based metric traditionally used to evaluate liver disease. Recent research suggests it may reflect metabolic shifts, such as the Warburg effect, which are associated with tumor progression and aggressive cellular proliferation. This meta-analysis seeks to consolidate fragmented and inconsistent evidence to determine if the De Ritis ratio can serve as a reliable, low-cost prognostic tool for bladder cancer.
Methodology
This study follows the formal roadmap established in the INPLASY protocol (Registration No: INPLASY202260024).
Search Strategy and Study Selection
A comprehensive search will be conducted across major medical databases, including PubMed, Embase, and the Cochrane Library, with no time restrictions. The review will focus on retrospective studies involving bladder cancer patients that report survival outcomes (e.g., Overall Survival, Progression-Free Survival) in relation to the De Ritis ratio. Only English-language literature will be included in the final synthesis.
Quality Assessment
The quality of the included studies will be rigorously evaluated using the Newcastle-Ottawa Scale (NOS). This assessment evaluates studies across three key domains: the selection of study cohorts, the comparability of those cohorts, and the ascertainment of the exposure or outcome of interest.
Statistical Analysis
The primary outcome measure for this meta-analysis will be the pooled Hazard Ratio (HR). Data synthesis will utilize both fixed and random-effects models to ensure robust results. Heterogeneity among studies will be quantified using the $I^2$ statistic, with values exceeding 60% indicating significant variation. To explore potential sources of heterogeneity, the researchers will perform subgroup analyses based on:
- Geographic region (Country)
- Therapeutic intervention (e.g., surgery vs. chemotherapy)
- Sample size
- Tumor stage
- Specific De Ritis ratio cut-off values used in individual studies
Statistical analyses will be performed using Review Manager 5.3 and Stata software.
Discussion and Significance
The De Ritis ratio is particularly attractive for clinical use because it is derived from standard liver function tests, which are inexpensive and routinely performed in most clinical settings. From a biological perspective, an elevated ratio may indicate a shift toward anaerobic glycolysis, a hallmark of aggressive cancer metabolism. While previous meta-analyses have explored this topic, the authors of this protocol aim to address prior limitations—such as inconsistent inclusion criteria—through a more rigorous and comprehensive statistical framework.
Current Status and Limitations
As this is a protocol, the research is currently in the data extraction phase. No quantitative results regarding the ratio's predictive power are available yet. Potential limitations of the upcoming study include its reliance on retrospective data, which is more prone to bias than prospective trials, and the potential for language bias due to the exclusion of non-English publications.
Conclusion
This meta-analysis will provide a definitive assessment of the De Ritis ratio's prognostic value in bladder cancer. If validated, this ratio could offer clinicians a simple, non-invasive method to stratify patient risk and tailor treatment plans more effectively, ultimately improving patient outcomes through better-informed clinical decisions.
Summary updated